Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Dow Jones

May 07, 2025

0711 GMT - Novo Nordisk shares will probably come under some pressure today, falling between 2% and 4%, as it delivered a downgrade following after a weak quarter for Wegovy which was pressured by generic drugs, Jyske Bank senior analyst Henrik Hallengreen Laustsen writes. The downgrade probably overshadows the fact that total sales are in line with expectations and that earnings surprise positively, he adds. The fear in the market was that Novo would downgrade - the fear came true, he says. Novo Nordisk now expects revenue growth of 13%-21% and earnings growth of 16%-24%, with the market looking for 17.8% and 21.5%, respectively. Guidance is lowered due to competition from generic drugs and the decline in the U.S. dollar. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

May 07, 2025 03:11 ET (07:11 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533624755"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533624755\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533624755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 15:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533624755","market":"sg","top_or_hot":-1,"title":"Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0711 GMT - Novo Nordisk shares will probably come under some pressure today, falling between 2% and 4%, as it delivered a downgrade following after a weak quarter for Wegovy which was pressured by generic drugs, Jyske Bank senior analyst Henrik Hallengreen Laustsen writes. The downgrade probably overshadows the fact that total sales are in line with expectations and that earnings surprise positively, he adds. The fear in the market was that Novo would downgrade - the fear came true, he says. Novo Nordisk now expects revenue growth of 13%-21% and earnings growth of 16%-24%, with the market looking for 17.8% and 21.5%, respectively. Guidance is lowered due to competition from generic drugs and the decline in the U.S. dollar. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 03:11 ET (07:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 15:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0711 GMT - Novo Nordisk shares will probably come under some pressure today, falling between 2% and 4%, as it delivered a downgrade following after a weak quarter for Wegovy which was pressured by generic drugs, Jyske Bank senior analyst Henrik Hallengreen Laustsen writes. The downgrade probably overshadows the fact that total sales are in line with expectations and that earnings surprise positively, he adds. The fear in the market was that Novo would downgrade - the fear came true, he says. Novo Nordisk now expects revenue growth of 13%-21% and earnings growth of 16%-24%, with the market looking for 17.8% and 21.5%, respectively. Guidance is lowered due to competition from generic drugs and the decline in the U.S. dollar. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 03:11 ET (07:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533624755","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533624755","pubTimestamp":1746601860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0711 GMT - Novo Nordisk shares will probably come under some pressure today, falling between 2% and 4%, as it delivered a downgrade following after a weak quarter for Wegovy which was pressured by generic drugs, Jyske Bank senior analyst Henrik Hallengreen Laustsen writes. The downgrade probably overshadows the fact that total sales are in line with expectations and that earnings surprise positively, he adds. The fear in the market was that Novo would downgrade - the fear came true, he says. Novo Nordisk now expects revenue growth of 13%-21% and earnings growth of 16%-24%, with the market looking for 17.8% and 21.5%, respectively. Guidance is lowered due to competition from generic drugs and the decline in the U.S. dollar. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德股价在降级后面临压力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0711 GMT - Novo Nordisk shares will probably come under some pressure today, falling between 2% and 4%, as it delivered a downgrade following after a weak quarter for Wegovy which was pressured by generic drugs, Jyske Bank senior analyst Henrik Hallengreen Laustsen writes. The downgrade probably overshadows the fact that total sales are in line with expectations and that earnings surprise positively, he adds. The fear in the market was that Novo would downgrade - the fear came true, he says. Novo Nordisk now expects revenue growth of 13%-21% and earnings growth of 16%-24%, with the market looking for 17.8% and 21.5%, respectively. Guidance is lowered due to competition from generic drugs and the decline in the U.S. dollar. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2025 03:11 ET (07:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}